Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818
Proposed [GID-HST10040] Expected publication date: TBC
Search results
177 results
-
-
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]
Proposed [GID-HST10038] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Proposed [GID-TA10681] Expected publication date: TBC
-
Ibalizumabtreating for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Proposed [GID-TA10657] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Proposed [GID-TA10720] Expected publication date: TBC
-
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Proposed [GID-TA10605] Expected publication date: TBC
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Proposed [GID-TA10764] Expected publication date: TBC
-
Semaglutide for managing overweight and obesity [ID3850]
Proposed [GID-TA10765] Expected publication date: TBC
-
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
Proposed [GID-TA10788] Expected publication date: TBC
-
Timrepigene emparvovec for treating choroideremia [ID3916]
Proposed [GID-TA10787] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
Proposed [GID-TA10786] Expected publication date: TBC
-
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]
Proposed [GID-TA10785] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]
Proposed [GID-TA10784] Expected publication date: TBC
-
Pegunigalsidase alfa for treating Fabry disease [ID3904]
Proposed [GID-TA10790] Expected publication date: TBC
-
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]
Proposed [GID-TA10789] Expected publication date: TBC
-
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Proposed [GID-TA10783] Expected publication date: TBC
-
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Proposed [GID-TA10791] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Proposed [GID-TA10795] Expected publication date: TBC
-
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]
Proposed [GID-TA10792] Expected publication date: TBC
-
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]
Proposed [GID-TA10796] Expected publication date: TBC
-
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]
Proposed [GID-TA10793] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Proposed [GID-TA10797] Expected publication date: TBC
-
Brolucizumab for treating diabetic macular oedema [ID3902]
Proposed [GID-TA10794] Expected publication date: TBC
-
Faricimab for treating diabetic macular oedema [ID3899]
Proposed [GID-TA10798] Expected publication date: TBC
-
Faricimab for treating wet age-related macular degeneration [ID3898 ]
Proposed [GID-TA10799] Expected publication date: TBC
-
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Proposed [GID-TA10800] Expected publication date: TBC
-
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]
Proposed [GID-TA10801] Expected publication date: TBC